VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MGTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MGTXMeiraGTx Holdings plc
$8.74$809M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
MGTX logo

MeiraGTx Holdings plc

MGTX
NASDAQ · Cell & Gene Therapy
$8.74
At close - Nov 16, 4:00 PM EST - USD
Market Cap$809M
P/E10.8x
52W High$15.35
Volume706.06K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Milestone-Driven Revenue Masks Persistent Operating Cash Burn

MeiraGTx's reported profitability in 2026Q2, with revenue of $321.4M and net income of $160.7M, appears to reflect a single milestone recognition event rather than recurring commercial demand, as the company posted a -$51.2M net loss in 2026Q3 and operating cash outflow of -$38.5M in the same prior quarter.

GrowthMixed
ProfitabilityWeak
ValuationAttractive
TechnicalsWeak
Explore valuation models
MARKET ACTION

MGTX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

4/12 Beats

EPS beat 4 of last 12 quarters

02

Valuation risk

-48% Peers

P/E is 48% below peer median

03

Market leadership

RS 43 · Lag

Laggard (Underperforming 57% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 12

Market performance

Price History →

Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
MGTX+11.91%
S&P 500 (^GSPC)+8.31%
1-Year Return
MGTX+10.91%
S&P 500 (^GSPC)+11.16%
3-Year Return
MGTX+71.04%
S&P 500 (^GSPC)+43.77%
5-Year Return
MGTX-56.34%
S&P 500 (^GSPC)+50.43%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
10.8x
Forward P/E
29.1x
EV/EBITDA
4.3x
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
10.8x
N/A
N/A
EV/EBITDA
4.3x
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$4.00-54.2%
Base (Fair)$7.12-34.7%
Bull$7.96-8.9%
$4.00 Bear$7.12 Base$7.96 Bull
Current Market Price: $8.74
Trades at a 22.8% premium to Base DCF ($7.12)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$81M+144.6% YoY
Net income FY25
-$114M+22.7% YoY
Free cash flow FY25
-$50M+54.1% YoY
Operating margin FY25
-130.2%+363.2 pts YoY
ROIC (FY25)-241.1%
Avg ROIC 5Y-142%
ROE (TTM)85.3%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate4/12 (33%)
Revenue Beat Rate4/12 (33%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 12, 2026
-$0.53-6.0%
vs -$0.50
$5M-30.8%
vs $7M
Q3 2026
Aug 13, 2026
$1.71+473.1%
vs -$0.46
$321M+45819.1%
vs $700,000
Q2 2026
May 14, 2026
-$0.57-32.6%
vs -$0.43
$293,000-98.3%
vs $17M
Q2 2026
Mar 26, 2026
$0.19+131.7%
vs -$0.60
$75M+5115.3%
vs $1M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Zacks Investment Research·4d ago
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates

MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.62 per share a year ago.

GlobeNewsWire·4d ago
MeiraGTx Reports Third Quarter 2026 Financial and Operational Results

Submission of Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) expected in December 2026  Submission of full Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bota-vec expected in the first quarter of 2027 12-month data readout in pivotal Phase 2 AQUAx2 study of AAV2-hAQP1 for the treatment of radiation-induced xerostomia (RIX) mid-2027 Upcoming oral presentation at ObesityWeek highlights AAV-BDNF program for the treatment of MC4R/BDNF genetic obesity (severe early-onset syndromic obesity) Strengthened leadership with the appointment of John Knighton as Executive Vice President of Global Manufacturing and Supply Chain and Alan M. Sebulsky to the Board of Directors LONDON and NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, 2026, and provided a corporate update.

GlobeNewsWire·Oct 27, 2026
MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy Platforms Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy Platforms

Defense World·Sep 30, 2026
Financial Contrast: MeiraGTx (NASDAQ:MGTX) & aTyr Pharma (NASDAQ:ATYR)

MeiraGTx (NASDAQ: MGTX - Get Free Report) and aTyr Pharma (NASDAQ: ATYR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Valuation and Earnings This table compares MeiraGTx and

Filtered for MeiraGTx Holdings plcMore Headlines
04

Compare before deciding

Benchmark MGTX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for MeiraGTx Holdings plc (MGTX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
MGTX logoMGTXMeiraGTx Holdings plcCurrent
$8.74$809.41M10.82144.57%19.48%85.3%—
OCGN logoOCGNOcugen, Inc.
$0.77$262.13M-4.018.83%-1367.61%——
EDIT logoEDITEditas Medicine, Inc.
$1.87$286.97M-3.9825.39%-144.95%-130.43%—
CRSP logoCRSPCRISPR Therapeutics AG
$40.37$3.89B-8.56-89.97%-1812.07%-25.59%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$9.86$1.11B-3.2416.92%-805.75%-64.73%—
BEAM logoBEAMBeam Therapeutics Inc.
$20.94$2.15B-20.47120.01%-73.04%-9.69%—

Compare MGTX vs Peers

MeiraGTx Holdings plc (MGTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs OCGN

Most directly comparable listed peer for MGTX.

Scale Benchmark

vs REGN

Larger-name benchmark to compare MGTX against a more recognizable public peer.

Peer Set

Compare Top 5

vs OCGN, EDIT, CRSP, NTLA

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

MGTX SEC Filings & Documents

MeiraGTx Holdings plc (MGTX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 12, 2026·SEC

Material company update

Aug 13, 2026·SEC

Material company update

Jul 7, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 30, 2026·SEC

FY 2025

Mar 13, 2025·SEC

FY 2024

Mar 15, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 12, 2026·SEC

FY 2026

Aug 13, 2026·SEC

FY 2026

May 14, 2026·SEC

Get notified when MGTX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

MGTX Frequently Asked Questions

MeiraGTx Holdings plc (MGTX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is MeiraGTx Holdings plc's revenue?

MeiraGTx Holdings plc (MGTX) reported $401.9M in revenue over the trailing twelve months. Revenue was $81.4M in fiscal year 2025.

How fast is MeiraGTx Holdings plc growing?

MeiraGTx Holdings plc (MGTX) grew revenue by 1365.9% over the trailing twelve months, compared with the twelve months before.

Is MGTX profitable?

Yes. MeiraGTx Holdings plc (MGTX) earned $78.3M in net income over the trailing twelve months (a 19.5% net margin).

Dividend & Returns
What is MGTX's return on equity?

MeiraGTx Holdings plc (MGTX) had a return on equity (ROE) of 85.3% over the trailing twelve months. That is well above the market's typical 10-15%.

What is MeiraGTx Holdings plc's free cash flow?

MeiraGTx Holdings plc (MGTX) had negative free cash flow of $9.5M over the trailing twelve months.

What if you invested $1,000 in MGTX back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →